Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $401,220.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $74.30, for a total transaction of $401,220.00. Following the transaction, the chief executive officer directly owned 344,489 shares in the company, valued at approximately $25,595,532.70. This represents a 1.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Down 0.9%

ANIP opened at $72.83 on Friday. ANI Pharmaceuticals, Inc. has a 12 month low of $70.15 and a 12 month high of $99.50. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The business’s 50-day moving average price is $79.68 and its 200-day moving average price is $78.65. The company has a market cap of $1.67 billion, a P/E ratio of 15.70 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. During the same quarter in the prior year, the company posted $1.80 EPS. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ANIP shares. Canaccord Genuity Group reduced their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Guggenheim decreased their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Finally, Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.83.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the company. KBC Group NV purchased a new stake in shares of ANI Pharmaceuticals during the first quarter valued at $28,000. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals in the 1st quarter worth about $28,000. Hantz Financial Services Inc. lifted its stake in ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 249 shares during the period. Kemnay Advisory Services Inc. bought a new position in ANI Pharmaceuticals during the 4th quarter valued at about $48,000. Finally, State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $50,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.